← Back to patent-cliff list
Naltrexone controlled-release (Alkermes)
Tier C — Watch / tradeNaltrexone controlled-release (Alkermes)
Alkermes Inc
Originator
2006
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MOR1
Brand：Vivitrex, Vivitrol
Indications (approved)：Opioid dependence, Alcohol abstinence
Regional status
US
Approved
2006-04-13
EU
No progress
2008-06-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Naltrexone controlled-release (Alkermes)?
Approved indications include: Opioid dependence, Alcohol abstinence.
When does the Naltrexone controlled-release (Alkermes) patent expire?
No public expiry year is available for Naltrexone controlled-release (Alkermes) yet; this page updates once verified.
How do I get a quote for Naltrexone controlled-release (Alkermes) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29